布加替尼治疗ALK融合基因阳性肺腺癌2例阿勒替尼诱导的间质性肺病

Q4 Medicine

Japanese Journal of Lung Cancer Pub Date : 2022-12-20 DOI:10.2482/haigan.62.1038

Yuta Nagahisa, Toshiyuki Sumi, M. Sekikawa, K. Takeda, Keigo Matsuura, Hiroki Watanabe, Yuichi Yamada, Yoshiko Keira, H. Chiba

{"title":"布加替尼治疗ALK融合基因阳性肺腺癌2例阿勒替尼诱导的间质性肺病","authors":"Yuta Nagahisa, Toshiyuki Sumi, M. Sekikawa, K. Takeda, Keigo Matsuura, Hiroki Watanabe, Yuichi Yamada, Yoshiko Keira, H. Chiba","doi":"10.2482/haigan.62.1038","DOIUrl":null,"url":null,"abstract":"━━ Background. Alectinib is an effective and well-tolerated agent for treating anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma. However, treatment with alectinib results in interstitial lung disease (ILD) as an adverse effect, thereby precluding therapy continuation. Several other ALK inhibitors have been studied in clinical trials","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Two Cases of ALK Fusion Gene-positive Lung Adenocarcinoma Treated with Brigatinib After Alectinib-induced Interstitial Lung Disease\",\"authors\":\"Yuta Nagahisa, Toshiyuki Sumi, M. Sekikawa, K. Takeda, Keigo Matsuura, Hiroki Watanabe, Yuichi Yamada, Yoshiko Keira, H. Chiba\",\"doi\":\"10.2482/haigan.62.1038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"━━ Background. Alectinib is an effective and well-tolerated agent for treating anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma. However, treatment with alectinib results in interstitial lung disease (ILD) as an adverse effect, thereby precluding therapy continuation. Several other ALK inhibitors have been studied in clinical trials\",\"PeriodicalId\":35081,\"journal\":{\"name\":\"Japanese Journal of Lung Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Lung Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2482/haigan.62.1038\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Lung Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2482/haigan.62.1038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

摘要

━━ 背景Alectinib是一种治疗间变性淋巴瘤激酶（ALK）融合基因阳性肺腺癌的有效且耐受性良好的药物。然而，阿来替尼治疗会导致间质性肺病（ILD）的不良反应，从而阻碍了治疗的继续。其他几种ALK抑制剂已在临床试验中进行了研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Two Cases of ALK Fusion Gene-positive Lung Adenocarcinoma Treated with Brigatinib After Alectinib-induced Interstitial Lung Disease

━━ Background. Alectinib is an effective and well-tolerated agent for treating anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma. However, treatment with alectinib results in interstitial lung disease (ILD) as an adverse effect, thereby precluding therapy continuation. Several other ALK inhibitors have been studied in clinical trials

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Japanese Journal of Lung Cancer Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量